The US FDA Puts Clinical Hold on Iovance Biotherapeutics’ (IOV-LUN-202) Trial of LN-145 for Non-Small Cell Lung Cancer
Shots:
- The trial has been halted on Dec 22, 2023 due to grade 5 (fatal) SAE potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen
- The (IOV-LUN-202) study assesses LN-145 in advanced NSCLC patients who progressed after CT and anti-PD-1 therapy, without EGFR, ROS, or ALK genomic mutations and have received targeted therapy if indicated by other actionable tumor mutations and have undergone at least one line of targeted therapy
- Furthermore, Iovance will halt enrollment and the LN-145 TIL treatment regimen for new patients while the previous treated patients with LN-145 in the trial will continue to be monitored as per the protocol. For patients who have undergone tumor resection, the LN-145 TIL treatment regimen will continue with added precautions and risk mitigations
Ref: Iovance Biotherapeutics | Image: Iovance Biotherapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
